



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_496_25

You asked:

I would be grateful if you could tell me how many patients were treated by individual drugs from the dermatology, gastroenterology, and rheumatology departments (for any disease) for the three-month period specified within the question.

I have provided a grid of drug names and department names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

Appendix A

Q1a – How many patients were treated with the following drugs from the following departments (for any disease) from the start of July 2025 to the end of September 2025?

Please use the latest available 3 months if July to September is not available and specify which 3 months have been used.

Our response:

Please find below a table providing the information that Medicines Management are able to provide at this current time. The period the data relates to July 25 to September 2025 as requested.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab	74	230	523
Apremilast	64	0	18
Bimekizumab	17	0	43
Brodalumab	**	0	0
Certolizumab Pegol	**	**	67
Deucravacitinib	22	0	0
Etanercept	**	0	279
Etrasimod	0	0	0
Filgotinib	0	**	13
Golimumab	0	0	58
Guselkumab	54	0	**
Infliximab (Biosimilars)	**	262	22
Infliximab (Remicade)	0	0	**
Ixekizumab	18	0	29
Mirikizumab	0	0	0
Ozanimod	0	0	0

Risankizumab	72	40	0
Secukinumab	9	0	100
Tildrakizumab	14	0	0
Tofacitinib	0	**	8
Upadacitinib	14	52	36
Ustekinumab	43	199	19
Vedolizumab	235	0	0

Please note - Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.